Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride

Author(s):  Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly

Issue:  Jan/Feb 2018 - Volume 22, Number 1
View All Articles in Issue

Abstract:  Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine- 3 (5-HT3) RA, and dexamethasone is recommended by international antiemesis guidelines for the prevention of chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy and for select patients receiving moderately emetogenic chemotherapy. VARUBI (rolapitant) is a substance P/NK-1 RA that was recently approved by the U.S. Food and Drug Administration as an injectable emulsion in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Granisetron Hydrochloride Injection USP is one of the 5-HT3 RAs indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Herein, we describe the physical and chemical compatibility and stability of VARUBI (rolapitant) injectable emulsion (166.5 mg/92.5 mL [1.8 mg/mL], equivalent to 185 mg of rolapitant hydrochloride) admixed with Granisetron Hydrochloride Injection USP (1.0 mg/mL, equivalent to 1.12 mg/mL hydrochloride). Binary admixtures of VARUBI injectable emulsion and Granisetron Hydrochloride Injection USP were prepared and stored in VARUBI ready-to-use glass vials and in four types of commonly used intravenous administration (tubing) sets. Evaluation of the physical and chemical compatibility and stability of the admixtures in the VARUBI ready-to-use vials stored at room temperature (20°C to 25°C) under fluorescent light and under refrigeration (2°C to 8°C protected from light) was conducted at 0, 1, 6, 24, and 48 hours, and that of the admixtures in the intravenous tubing sets was evaluated at 0, 2, and 6 hours of storage at 20°C to 25°C. Physical stability was evaluated by visual examination of the container contents under normal room light, and measurement of turbidity, globule size, and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations (potency) and impurity levels by high-performance liquid chromatographic analysis. The pH, turbidity, globule size, and particulate matter of all samples remained within narrow and acceptable ranges at all study time points, indicating that combining the two formulations into a binary admixture is physically and chemically compatible and stable. VARUBI injectable emulsion admixed with Granisetron Hydrochloride Injection USP demonstrated compatibility and stability in a ready-to-use glass vial for at least 24 hours at room temperature and 48 hours under refrigeration, as well as in the four intravenous tubing sets for at least 6 hours at 20°C to 25°C. No decrease of drug concentration (or potency) of any admixed components occurred in the samples stored at the two conditions and time periods studied based on high-performance liquid chromatographic analysis. The levels of impurities stayed below the safety limits set by International Conference on Harmonisation during the study period.

Related Keywords: George Wu, PhD, Dan Powers, DO, Stanley Yeung, PharmD, Frank Chen, PhD, Kelly Neelon, PhD, VARUBI, injectable emulsion, chemotherapy-induced nausea and vomiting, neurokinin 1 receptor antagonist, substance P receptor antagonist, emesis, antiemetic agent, triple combination therapy, 5-HT3 receptor antagonist, dexamethasone, rolapitant, drug admixtures, stability studies, granisetron hydrochloride, storage conditions, intravenous tubing set compatibility

Related Categories: CANCER AND AIDS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION, NEUROLOGY

Printer-Friendly Version




Download in electronic PDF format for $45

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly Jan/Feb 2018 86-94 Buy
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection Wu George, Powers Dan, Yeung Stanley, Chen Frank Jan/Feb 2018 76-85 Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Wu George, Yeung Stanley, Chen Frank Jan/Feb 2017 66-75 Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Wu George, Yeung Stanley, Chen Frank Jan/Feb 2017 76-82 Buy
Basics of Compounding for the Treatment of Warts Allen Loyd V Jr Mar/Apr 2004 126-129 Buy
Wetting and/or Solubilizing Agents, Featured Excipient: Allen Loyd V Jr Jul/Aug 2001 310-312 Buy
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture Allen Loyd V Jr Mar/Apr 2018 151 Buy
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain Mishkan Emilyn S Sep/Oct 2005 339-346 Buy
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture Allen Loyd V Jr May/Jun 2018 237 Buy
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso Jul/Aug 2014 278-286 Buy